Total: $880.25M
Company (Symbol)# Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (M) Investors; Placement Agents; Details (Date)@
Access Pharmaceuticals Inc. (OTC BB:ACCP) Private placement N/A $9.5 Access raised $9.5M through SCO Capital Partners and Perceptive Life Sciences; in addition, SCO, Oracle Partners and certain affiliates agreed to exchange $10M in senior debt into Series A convertible preferred stock (11/8)
Affymetrix Inc. (AFFY) Private placement of unsecured senior convertible notes N/A $275 Affymetrix priced the notes due 2038; J.P. Morgan Securities Inc. has an option to buy $41.25M in notes to cover any overallotments (11/14)
Ark Therapeutics Group (UK; LSE:AKT) Private placement of common stock 35.6S £35.4 ($73.8) Ark is raising $73.8M in the placement of 35.6M shares at £1.05 each (11/7**)
BioForce Nanosciences Holdings Inc. (OTC BB:BFNH) Exercise of Series C warrants N/A $0.5 BioForce received $500,000 in proceeds from the exercise of Series C warrants issued in a $500,000 August financing (11/19)
Bioxel Pharma Inc. (Canada; CDNX:BIP) Private placement of 15% convertible unsecured debentures 22.9W for 22.9S C$3.66 ($3.75) Bioxel raised $3.75M placing the debentures, which are convertible into common shares at a conversion price of C16 cents per share in the first two years, increasing by 10% each subsequent year; holders received 22.9M warrants to buy an equal number of common shares at an exercise price of C16 cents per share for two years from the date of closing (11/21)
BrainStorm Cell Therapeutics Inc. (OTC BB: BCLI) Private placement of common stock N/A $0.75 BrainStorm completed a second equity financing with ACCBT Corp. (11/12)
Cardium Therapeutics Inc. (AMEX:CXM) Credit facility N/A $5 Cardium's subsidiary InnerCool Therapies Inc. is receiving the money through Life Sciences Capital (11/15)
Cell Therapeutics Inc. (CTIC) Private placement of convertible preferred stock and warrants N/A $6.5 Cell Therapeutics raised $6.5M through the sale of 7% convertible preferred stock and warrants; Rodman & Renshaw acted as the exclusive placement agent (11/30)
Chelsea Therapeutics International Inc. (CHTP) Private placement of common stock 7.4S $48.9 Chelsea raised $48.9M offering 7.4M shares at $6.62 per share; Leerink Swann LLC served as lead placement agent, with Oppenheimer & Co. Inc. and Punk Ziegel & Co. serving as co-placement agents (11/2)
Crucell NV (the Netherlands; CRXL) Sale of equity stake N/A CHF10($8.9) Crucell's subsidiary, Berna Biotech AG, sold all of the 2.9M shares it owned in Switzerland-based Pevion Biotech Ltd., generating proceeds of $8.9M (11/12)
Epistem Holdings plc (UK; LSE:EHP) Private placement of common stock N/A £1.1 ($2.3) Epistem raised $2.3M by a placement of 653,806 shares (11/28**)
Epix Pharmaceuticals Inc. (EPIX) Private placement of common stock N/A $16.3 Epix raised $16.3M placing 5.2M shares at $3.10 each with institutional and accredited investors (11/12)
Favrille Inc. (FVRL) Registered direct offering 7.4S and W for 4.4S $21.1 Favrille raised $21.1M in the offering; Lazard Capital Markets LLC served as sole placement agent (11/5)
Genesis Pharmaceuticals Enterprises Inc. (China; OTC BB: GTEC) Private placement of convertible notes and common stock purchase warrants N/A $5 Genesis raised $5M in the placement (11/9)
Lev Pharmaceuticals Inc. (OTC BB: LEVP) Senior secured term loan facility N/A $10 The loan from MAST Capital Management LLC provides $10M initially and the option to borrow another $10M within the next 12 months (11/9)
Microbix Biosystems Inc. (Canada; TSX:MBX) Private placement of units 6.5U C$6.8 ($7.1) Microbix Biosystems raised $7.1M through the placement of 6.5M units priced at C$1.05 ($1.09) each; each unit consists of one common share and one-half of a five-year warrant to purchase an additional common share for C$1.26; Dundee Securities Corp. led the financing, which included J.F. Mackie & Company Ltd. (11/14)
MicroIslet Inc. (OTC BB: MIIS) Private placement of common stock 2.35S and W for 1.3S $1 MicroIslet entered into an agreement to sell common shares to a private trust for gross proceeds of $1M
Molecular Insight Pharmaceuticals Inc. (MIPI) Private placement of warrants W for 6S $150 Molecular Insight priced $150M in bonds due in 2012 with institutional investors (11/12)
Neuro-Hitech Inc. (NHPI) Private placement of common stock and warrants 1.3S and W for 0.625S $5 Neuro-Hitech raised $5M through the offering (11/30)
Neurologix Inc. (OTC BB: NRGX) Private placement of Series D convertible preferred stock S and W for 3.2S $15 Neurologix raised $15M in a private placement of Series D stock convertible into about 30.17 shares of common stock; the company also issued warrants to purchase about 3.2M shares at $1.39 each (11/26)
NeuroSearch A/S (Denmark; CSE:NEUR) Private placement of common stock N/A DKK728.7($145.2) NeuroSearch raised $145.2M through a discounted rights issue of 2.75M shares, priced at DKK280 each; Carnegie A/S and Danske Bank A/S acted as joint global coordinators of the offering (11/28**)
Ondine Biopharma Corp. (Canada; TSX:OBP) Private placement of units 5U C$5.5 ($5.6) Ondine raised $5.6M from a nonbrokered private placement of 5M units, each unit consisting of one common share and one-half of one common share purchase warrant, priced at C$1.10 each (11/26)
Pharmaxis Ltd. (Australia; PXSL) Share purchase plan 3S A$11.7 ($10.5) Pharmaxis raised $10.5M; shareholders were able to buy up to $5,000 worth of shares each at the A$3.90 price paid by institutional investors in a A$50M placement last month (11/19)
Pipex Pharmaceuticals Inc. (AMEX:PP) Exercise of warrants N/A $7.3 Pipex received about $7.3M through the exercise of warrants to purchase the company's commonstock (11/16)
Prana Biotechnology Ltd. (Australia; PRAN) Private placement N/A $1.5 Prana closed a placement, raising A$8M ($7.4M); $5.9M of the total was accounted for in the September chart (11/1)
Protox Therapeutics Inc. (Canada; CDNX:PRX) Exercise of warrants N/A C$2.47 ($2.5) Protox received more money from the exercise of warrants issued during a 2005 private placement, bringing the total raised to C$7.6M ($7.7M); some of the money was accounted for in the October chart (11/20)
Scolr Pharma Inc. (AMEX:DDD) Private placement of common stock 2.7S and W for 1.3S $4.05 Scolr Pharma sold about 2.7M shares at $1.50 each; buyers also received five-year warrants to purchase about 1.3M shares, exercisable at $2.10 each (11/29)
SGX Pharmaceuticals Inc. (SGXP) Private placement of common stock and warrants 4.9S and W for 1.5S $25 SGX raised $25M in a private placement of units consisting of one share and a warrant to purchase 0.3 shares, priced at $5.06 each; Lazard Freres & Co. acted as the exclusive placement agent for the transaction (11/20)
Stem Cell Therapeutics Corp. (Canada; CDNX:SSS) Bought deal financing N/A C$12.08 ($13.2) Stem Cell raised $13.2M through Dundee Securities Corp., J.F. Mackie & Co. Ltd., Fraser Mackenzie Ltd., Loewen, Ondaatje, McCutcheon Ltd. and Research Capital Corp. (11/9)
Notes:

This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Funds from loan facilities are included only when the company takes a draw, if announced.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange

@ Refers to the date of the press release.

** Denotes the date the item ran in BioWorld International.

Currency conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.